A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis-Reference-Cited by-同舟云学术

A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis

Published:2022-08 Issue:8 Volume:6 Page:e757
ISSN:2572-9241
Container-title:HemaSphere
language:en
Short-container-title:

Author:

Harrison Claire,Heidel Florian H.,Vannucchi Alessandro M.,Kiladjian Jean-Jacques,Hayat Amjad,Passamonti Francesco,Conneally Eibhlin,Kindler Thomas,Martino Bruno,Lipka Daniel B.,Stefanelli Tommaso,Roussou Pantelia,Germano Davide,Ewan Jacqueline,Ribrag Vincent

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Hematology

Reference15 articles.

1. Treatment and management of myelofibrosis in the era of JAK inhibitors.;Keohane;Biologics,2013

2. Primary myelofibrosis: update on definition, pathogenesis, and treatment.;Abdel-Wahab;Annu Rev Med,2009

3. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.;Cervantes;Blood,2009

4. A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF).;Mascarenhas;Br J Haematol,2013

5. JAK1/2 and Pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease.;Evrot;Clin Cancer Res,2013

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements;Cancers;2024-01-25

2. Myelofibrosis;Blood;2022-11-23